Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 15;23(8):617-624.
doi: 10.1631/jzus.B2200113.

Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features

Sergey Vtorushin  1   2 , Anastasia Dulesova  3 , Nadezhda Krakhmal  4   5
Affiliations
Review

Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features

Sergey Vtorushin et al. J Zhejiang Univ Sci B. .

Abstract

According to the classification presented by Lehmann BD (2016), triple-negative breast cancer (TNBC) is a heterogeneous group of malignant tumors with four specific subtypes: basal-like (subtype 1 and subtype 2), mesenchymal, and luminal androgen receptor (LAR) subtypes. The basal-like subtypes of carcinomas predominate in this group, accounting for up to 80% of all cases. Despite the significantly lower proportions of mesenchymal and LAR variants in the group of breast carcinomas with a TNBC profile, such tumors are characterized by aggressive biological behavior. To this end, the LAR subtype is of particular interest, since the literature on such tumors presents different and even contradictory data concerning the disease course and prognosis. This review is devoted to the analysis of the relevant literature, reflecting the main results of studies on the molecular properties and clinical features of the disease course of LAR-type TNBC carcinomas.

Keywords: Androgen receptor (AR); Luminal androgen receptor (LAR) subtype; Prognosis; Triple-negative breast cancer (TNBC).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abd El-Rehim DM, Pinder SE, Paish CE, et al. , 2004. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol, 203(2): 661-671. 10.1002/path.1559 - DOI - PubMed
    1. Ali AM, Ansari JAK, Abd El-Aziz NM, et al. , 2017. Triple negative breast cancer: a tale of two decades. Anticancer Agents Med Chem, 17(4): 491-499. 10.2174/1871520616666160725112335 - DOI - PubMed
    1. Anestis A, Zoi I, Papavassiliou AG, et al. , 2020. Androgen receptor in breast cancer—clinical and preclinical research insights. Molecules, 25(2): 358. 10.3390/molecules25020358 - DOI - PMC - PubMed
    1. Asano Y, Kashiwagi S, Onoda N, et al. , 2016. Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer. Br J Cancer, 114(1): 14-20. 10.1038/bjc.2015.434 - DOI - PMC - PubMed
    1. Asghar US, Barr AR, Cutts R, et al. , 2017. Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer. Clin Cancer Res, 23(18): 5561-5572. 10.1158/1078-0432.CCR-17-0369 - DOI - PMC - PubMed

Substances